Payment overview · 2025
General Payments
$616.47
26 reported records · 14 companies
Healthcare provider profile · identity verified
Nitin Govani, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKEWOOD, OH · NPI 1619079050
Verified facts
What the public records show
CMS Open Payments records show Nitin Govani, MD received $616.47 in general payments during 2025 across 26 reported records.
Olympus America Inc. accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 535 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 535 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Olympus America Inc. | Unresolved — no canonical attribution shown | $138.31 | 22.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $110.46 | 17.9% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.50 | 10.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $49.00 | 8.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.85 | 7.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $40.30 | 6.5% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.89 | 5.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.66 | 5.0% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $22.17 | 3.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.98 | 2.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.68 | 2.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.67 | 2.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.53 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.47 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $616.47 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| iTIND System Normalized: itind system |
Device | Olympus America Inc. | $138.31 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $89.30 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.50 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $59.23 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.84 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $31.89 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $31.89 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.66 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.66 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.48 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 535 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
535 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
535 | 58 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1094 | 229 |
| Levothyroxine Sodium | Levothyroxine Sodium | 826 | 120 |
| Eliquis | Apixaban | 535 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 465 | 98 |
| Gabapentin | Gabapentin | 458 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 430 | 97 |
| Sertraline Hcl | Sertraline Hcl | 417 | 69 |
| Furosemide | Furosemide | 409 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 391 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 383 | 73 |
| Donepezil Hcl | Donepezil Hcl | 312 | 47 |
| Potassium Chloride | Potassium Chloride | 297 | 64 |
| Trazodone Hcl | Trazodone Hcl | 284 | 60 |
| Mirtazapine | Mirtazapine | 275 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 270 | 57 |
| Metformin Hcl | Metformin Hcl | 256 | 60 |
| Lisinopril | Lisinopril | 249 | 59 |
| Omeprazole | Omeprazole | 244 | 68 |
| Losartan Potassium | Losartan Potassium | 226 | 51 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 187 | 34 |
| Carvedilol | Carvedilol | 177 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 161 | 29 |
| Memantine Hcl | Memantine Hcl | 154 | 26 |
| Tramadol Hcl | Tramadol Hcl | 150 | 25 |
| Meloxicam | Meloxicam | 140 | 39 |
| Allopurinol | Allopurinol | 137 | 28 |
| Divalproex Sodium | Divalproex Sodium | 133 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 132 | 17 |
| Simvastatin | Simvastatin | 131 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 121 | 15 |
| Myrbetriq | Mirabegron | 112 | 15 |
| Latanoprost | Latanoprost | 108 | 22 |
| Prednisone | Prednisone | 108 | 64 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 16 |
| Risperidone | Risperidone | 105 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 23 |
| Finasteride | Finasteride | 103 | 23 |
| Spironolactone | Spironolactone | 93 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 22 |
| Midodrine Hcl | Midodrine Hcl | 89 | 17 |
| Torsemide | Torsemide | 82 | 19 |
| Atenolol | Atenolol | 81 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 30 |
| Januvia | Sitagliptin Phosphate | 76 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 75 | 15 |
| Baclofen | Baclofen | 73 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 49 |
| Montelukast Sodium | Montelukast Sodium | 72 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 70 | 53 |
| Lorazepam | Lorazepam | 69 | 18 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 68 | 12 |
| Buspirone Hcl | Buspirone Hcl | 67 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 12 |
| Alprazolam | Alprazolam | 66 | suppressed |
| Xarelto | Rivaroxaban | 66 | 11 |
| Celecoxib | Celecoxib | 63 | 15 |
| Cinacalcet Hcl | Cinacalcet Hcl | 63 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 59 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | suppressed |
| Famotidine | Famotidine | 57 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 14 |
| Levetiracetam | Levetiracetam | 55 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 12 |
| Bupropion Xl | Bupropion Hcl | 54 | suppressed |
| Lamotrigine | Lamotrigine | 53 | suppressed |
| Trulicity | Dulaglutide | 53 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Creon | Lipase/Protease/Amylase | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 20 |
| Lactulose | Lactulose | 46 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 18 |
| Ezetimibe | Ezetimibe | 45 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 25 |
| Azithromycin | Azithromycin | 44 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 16 |
| Oxcarbazepine | Oxcarbazepine | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 16 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 16 |
| Lithium Carbonate | Lithium Carbonate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Methotrexate | Methotrexate Sodium | 31 | suppressed |
| Metolazone | Metolazone | 31 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | 21 |
| Levofloxacin | Levofloxacin | 30 | 17 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | 14 |
| Nystatin | Nystatin | 28 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | 13 |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 22 | suppressed |
| Armour Thyroid | Thyroid,pork | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Valproic Acid | Valproic Acid | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 13 |
| Diclofenac Epolamine | Diclofenac Epolamine | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Acetic Acid | Acetic Acid | 19 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Oxaprozin | Oxaprozin | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 16 | suppressed |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Leucovorin Calcium | Leucovorin Calcium | 15 | suppressed |
| Permethrin | Permethrin | 15 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Dicloxacillin Sodium | Dicloxacillin Sodium | 14 | suppressed |
| Klayesta | Nystatin | 14 | 12 |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Aricept | Donepezil Hcl | 13 | suppressed |
| Captopril | Captopril | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | 11 |
| Mupirocin | Mupirocin | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 13 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 12 | 12 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Glyburide | Glyburide | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $616.47 · 26 records | Olympus America Inc. | AIRSUPRA, BREZTRI, CAMZYOS, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, FUROSCIX, GVOKE HYPOPEN, HETLIOZ, MOUNJARO, NURTEC ODT, PAXLOVID, QULIPTA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, ZEPBOUND, iTIND System | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error